UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)

Circulation (New York, N.Y.), 2018-01, Vol.137 (4), p.338-350

2018

Volltextzugriff (PDF)

Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER Trial

Journal of the American College of Cardiology, 2019-06, Vol.73 (23), p.2961-2970

2019

Volltextzugriff (PDF)

Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk: Insights From the FOURIER Trial

Circulation (New York, N.Y.), 2019-03, Vol.139 (12), p.1483-1492

2019

Volltextzugriff (PDF)

Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis

Stroke (1970), 2020-05, Vol.51 (5), p.1546-1554

2020

Volltextzugriff (PDF)

Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease: Analysis From FOURIER

Circulation (New York, N.Y.), 2018-08, Vol.138 (8), p.756-766

2018

Volltextzugriff (PDF)

The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism

Circulation (New York, N.Y.), 2020-05, Vol.141 (20), p.1600-1607

2020

Volltextzugriff (PDF)

Efficacy and safety of low-dose colchicine in patients with coronary disease: a systematic review and meta-analysis of randomized trials

European heart journal, 2021-07, Vol.42 (28), p.2765-2775

2021

Volltextzugriff (PDF)

New cardiovascular prevention guidelines: How to optimally manage dyslipidaemia and cardiovascular risk in 2021 in patients needing secondary prevention?

Atherosclerosis, 2021-02, Vol.319, p.51-61

2021

Volltextzugriff (PDF)

Predicting Benefit From Evolocumab Therapy in Patients With Atherosclerotic Disease Using a Genetic Risk Score: Results From the FOURIER Trial

Circulation (New York, N.Y.), 2020-02, Vol.141 (8), p.616-623

2020

Volltextzugriff (PDF)

Inflammatory and Cholesterol Risk in the FOURIER Trial

Circulation (New York, N.Y.), 2018-07, Vol.138 (2), p.131-140

2018

Volltextzugriff (PDF)

D-Dimer Predicts Long-Term Cause-Specific Mortality, Cardiovascular Events, and Cancer in Patients With Stable Coronary Heart Disease: LIPID Study

Circulation (New York, N.Y.), 2018-08, Vol.138 (7), p.712-723

2018

Volltextzugriff (PDF)

Cognition After Lowering LDL-Cholesterol With Evolocumab

Journal of the American College of Cardiology, 2020-05, Vol.75 (18), p.2283-2293

2020

Volltextzugriff (PDF)

Effect of Evolocumab on Complex Coronary Disease Requiring Revascularization

Journal of the American College of Cardiology, 2021-01, Vol.77 (3), p.259-267

2021

Volltextzugriff (PDF)

Cardiovascular Benefit of Lowering Low-Density Lipoprotein Cholesterol Below 40 mg/dL

Circulation (New York, N.Y.), 2021-11, Vol.144 (21), p.1732-1734

2021

Volltextzugriff (PDF)

Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial

The American heart journal, 2016-03, Vol.173, p.94-101

2016

Volltextzugriff (PDF)

Balloon warming time is the strongest predictor of late pulmonary vein electrical reconnection following cryoballoon ablation for atrial fibrillation

Heart rhythm, 2013-09, Vol.10 (9), p.1311-1317

2013

Volltextzugriff (PDF)

Effect of evolocumab on acute arterial events across all vascular territories : results from the FOURIER trial

European heart journal, 2021-12, Vol.42 (47), p.4821-4829

2021

Volltextzugriff (PDF)

Triglyceride-lowering trials

Current opinion in lipidology, 2017-12, Vol.28 (6), p.477-487

2017

Volltextzugriff (PDF)

Twelve-lead ambulatory electrocardiographic monitoring in Brugada syndrome: Potential diagnostic and prognostic implications

Heart rhythm, 2017-06, Vol.14 (6), p.866-874

2017

Volltextzugriff (PDF)

Cost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease

JAMA cardiology, 2017-10, Vol.2 (10), p.1069

2017

Volltextzugriff (PDF)

Association of Contemporary Sensitive Troponin I Levels at Baseline and Change at 1 Year With Long-Term Coronary Events Following Myocardial Infarction or Unstable Angina: Results From the LIPID Study (Long-Term Intervention With Pravastatin in Ischaemic Disease)

Journal of the American College of Cardiology, 2014-02, Vol.63 (4), p.345-354

2014

Volltextzugriff (PDF)

Effects of Fibrates in Kidney Disease

Journal of the American College of Cardiology, 2012-11, Vol.60 (20), p.2061-2071

2012

Volltextzugriff (PDF)

Clinical Application of a Novel Genetic Risk Score for Ischemic Stroke in Patients With Cardiometabolic Disease

Circulation (New York, N.Y.), 2021-02, Vol.143 (5), p.470-478

2021

Volltextzugriff (PDF)

Combining High-Sensitivity Troponin With the American Heart Association/American College of Cardiology Cholesterol Guidelines to Guide Evolocumab Therapy

Circulation (New York, N.Y.), 2021-07, Vol.144 (3), p.249-251

2021

Volltextzugriff (PDF)

Comparison of Low-Density Lipoprotein Cholesterol Assessment by Martin/Hopkins Estimation, Friedewald Estimation, and Preparative Ultracentrifugation: Insights From the FOURIER Trial

JAMA cardiology, 2018-08, Vol.3 (8), p.749

2018

Volltextzugriff (PDF)

1 – 25 von 87

Suche als RSS-Feed

Aktive Filter

ThemaCardiovascular System & Cardiology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(86)
Mit Volltextzugriff
(70)

Publikationsform

Artikel
(87)

Sprache

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(87)
Science & Technology
(87)
Cardiac & Cardiovascular Systems
(82)
Humans
(62)
Male
(41)
Female
(40)
Middle Aged
(37)
Aged
(34)
Peripheral Vascular Disease
(26)
Treatment Outcome
(24)
Risk Factors
(23)
Adult
(17)
Biological And Medical Sciences
(17)
Double-Blind Method
(17)
Medical Sciences
(17)
Anticholesteremic Agents - Therapeutic Use
(15)
Cardiovascular Disease
(15)
Cholesterol
(15)
Hydroxymethylglutaryl-Coa Reductase Inhibitors - Therapeutic Use
(15)

14 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)

Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER Trial

Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk: Insights From the FOURIER Trial

Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis

Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease: Analysis From FOURIER

The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism

Efficacy and safety of low-dose colchicine in patients with coronary disease: a systematic review and meta-analysis of randomized trials

New cardiovascular prevention guidelines: How to optimally manage dyslipidaemia and cardiovascular risk in 2021 in patients needing secondary prevention?

Predicting Benefit From Evolocumab Therapy in Patients With Atherosclerotic Disease Using a Genetic Risk Score: Results From the FOURIER Trial

Inflammatory and Cholesterol Risk in the FOURIER Trial

D-Dimer Predicts Long-Term Cause-Specific Mortality, Cardiovascular Events, and Cancer in Patients With Stable Coronary Heart Disease: LIPID Study

Cognition After Lowering LDL-Cholesterol With Evolocumab

Effect of Evolocumab on Complex Coronary Disease Requiring Revascularization

Cardiovascular Benefit of Lowering Low-Density Lipoprotein Cholesterol Below 40 mg/dL

Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial

Balloon warming time is the strongest predictor of late pulmonary vein electrical reconnection following cryoballoon ablation for atrial fibrillation

Effect of evolocumab on acute arterial events across all vascular territories : results from the FOURIER trial

Triglyceride-lowering trials

Twelve-lead ambulatory electrocardiographic monitoring in Brugada syndrome: Potential diagnostic and prognostic implications

Cost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease

Association of Contemporary Sensitive Troponin I Levels at Baseline and Change at 1 Year With Long-Term Coronary Events Following Myocardial Infarction or Unstable Angina: Results From the LIPID Study (Long-Term Intervention With Pravastatin in Ischaemic Disease)

Effects of Fibrates in Kidney Disease

Clinical Application of a Novel Genetic Risk Score for Ischemic Stroke in Patients With Cardiometabolic Disease

Combining High-Sensitivity Troponin With the American Heart Association/American College of Cardiology Cholesterol Guidelines to Guide Evolocumab Therapy

Comparison of Low-Density Lipoprotein Cholesterol Assessment by Martin/Hopkins Estimation, Friedewald Estimation, and Preparative Ultracentrifugation: Insights From the FOURIER Trial

Aktive Filter

Suchergebnisse filtern